Clinical Trials · NCT04126603
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Sabyasachi Sen
- Enrollment
- 10
- Start date
- Aug 2019
- Locations
- 2 sites, United States
- Primary endpoint
- CD34+ Endothelial Progenitor Cell Number (EPC) Per Mononuclear Cells (MNC) Ratio